The evolution of Taiwan’s National Health Insurance drug reimbursement scheme

מאת Hsu, Jason C, Lu, Christine Y
הוצא לאור ב Daru (2015)

Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study

מאת Hsu, Jason C, Lu, Christine Y
הוצא לאור ב BMJ Open (2016)

Comment on ‘Measuring the impact of medicines regulatory interventions – systematic review and methodological considerations’ by Goedecke et al.

מאת Lu, Christine Y., Soumerai, Stephen B.
הוצא לאור ב Br J Clin Pharmacol (2018)

Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States

מאת Hendricks-Sturrup, Rachele M., Lu, Christine Y.
הוצא לאור ב J Pers Med (2019)

Direct-to-Consumer Genetic Testing Data Privacy: Key Concerns and Recommendations Based on Consumer Perspectives

מאת Hendricks-Sturrup, Rachele M., Lu, Christine Y.
הוצא לאור ב J Pers Med (2019)

What motivates the sharing of consumer-generated genomic information?

מאת Hendricks-Sturrup, Rachele M, Lu, Christine Y
הוצא לאור ב SAGE Open Med (2020)

Counterpoint: Staying Honest When Policy Changes Backfire

מאת Lu, Christine Y, Simon, Gregory, Soumerai, Stephen B
הוצא לאור ב Med Care (2018)

Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies

מאת Gavan, Sean P., Lu, Christine Y., Payne, Katherine
הוצא לאור ב J Pers Med (2019)

Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand

מאת Leopold, Christine, Lu, Christine Y., Wagner, Anita K.
הוצא לאור ב BMC Health Serv Res (2020)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)

מאת Kim, Jeeyun A., Ceccarelli, Rachel, Lu, Christine Y.
הוצא לאור ב J Pers Med (2021)

The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines

מאת Lu, Christine Y, Williams, Kenneth M, Day, Richard O
יצא לאור 2007

The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia

מאת Lu, Christine Y, Ritchie, Jan, Williams, Ken, Day, Ric
יצא לאור 2007

Access to high cost medicines in Australia: ethical perspectives

מאת Lu, Christine Y, Macneill, Paul, Williams, Ken, Day, Ric
יצא לאור 2008

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

מאת Gammie, Todd, Lu, Christine Y., Babar, Zaheer Ud-Din
הוצא לאור ב PLoS One (2015)

10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan’s National Health Insurance Research Database

מאת Hsieh, Hsing-Chun, Hsu, Jason C, Lu, Christine Y
הוצא לאור ב BMJ Open (2017)

Geographic Variations and Time Trends in Cancer Treatments in Taiwan

מאת Hsu, Jason C., Chang, Sheng-Mao, Lu, Christine Y.
הוצא לאור ב BMC Public Health (2017)

Counterpoint: Early warning systems are imperfect, but essential

מאת Lu, Christine Y, Simon, Gregory, Soumerai, Stephen B, Kulldorff, Martin
הוצא לאור ב Med Care (2018)

A Qualitative Study to Develop a Privacy and Nondiscrimination Best Practice Framework for Personalized Wellness Programs

מאת Hendricks-Sturrup, Rachele M., Cerminara, Kathy L., Lu, Christine Y.
הוצא לאור ב J Pers Med (2020)

Recent developments in targeting access to high cost medicines in Australia

מאת Lu, Christine Y, Ritchie, Jan, Williams, Kenneth M, Day, Richard O
יצא לאור 2005

The Impact of the Orphan Drug Act on FDA-Approved Therapies for Rare Skin Diseases and Skin-Related Cancers

מאת Karas, Laura, Lu, Christine Y., Agrawal, Pankaj B., Asgari, Maryam M.
הוצא לאור ב J Am Acad Dermatol (2019)